Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Wednesday morning, Digital Look reports.
Other analysts have also recently issued research reports about the company. UBS Group reaffirmed a sell rating and set a GBX 5,700 ($74.48) target price on shares of AstraZeneca in a research report on Tuesday, September 10th. Citigroup reaffirmed a buy rating and set a £100 ($130.67) target price (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research report on Wednesday, September 11th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the company a sell rating in a research report on Monday, September 2nd. Credit Suisse Group set a GBX 7,300 ($95.39) price objective on AstraZeneca and gave the company a buy rating in a report on Friday, July 26th. Finally, Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of GBX 7,050 ($92.12).
Shares of LON AZN opened at GBX 7,167 ($93.65) on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48. The stock has a market capitalization of $94.02 billion and a PE ratio of 41.86. The stock’s fifty day simple moving average is GBX 7,191.39 and its two-hundred day simple moving average is GBX 6,415.44. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09).
The firm also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were issued a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 1.07%. AstraZeneca’s dividend payout ratio is presently 1.28%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is the Dividend Aristocrat Index?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.